# carlsmed.com

> AI-optimized mirror of carlsmed.com containing 194 pages totalling 224,686 words of clean markdown content, structured data, and semantic HTML. Original source: https://carlsmed.com. Last updated: 2026-07-26T02:27:05.629Z.

Each page is available as HTML (with JSON-LD structured data) and Markdown (text-only, ideal for LLMs and RAG).

## Homepage

- [Investor Relations | Carlsmed](/content/investors/index.html): Carlsmed Investor relations (IR) website contains information about our business for stockholders, potential investors, and financial analysts. (171 words)
- [Carlsmed](/content/site-root.html): Carlsmed® uses patient data and digital technologies to create optimal surgical plans and personalized aprevo® spine fusion devices., Transforming Spine Surgery Through Personalized Solutions
Our mission is to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. The Carlsmed aprevo® personalized surgery platform is designed to improve the standard of care for spine surgery one patient at a time. (326 words)

## Articles & Blog Posts

- [0001794546-26-000010 | 8-K | XBRL Viewer | Carlsmed INC](/content/investors/node/7206/xbrl-viewer/index.html): Carlsmed INC SEC filing: Form 8-K on 05/05/2026 (0001794546-26-000010) (XBRL) (1,209 words)
- [0001794546-26-000005 | DEF 14A | XBRL Viewer | Carlsmed INC](/content/investors/node/7156/xbrl-viewer/index.html): Carlsmed INC SEC filing: Form DEF 14A on 04/22/2026 (0001794546-26-000005) (XBRL) (867 words)
- [0001193125-26-255404 | 8-K | XBRL Viewer | Carlsmed INC](/content/investors/node/7221/xbrl-viewer/index.html): Carlsmed INC SEC filing: Form 8-K on 06/03/2026 (0001193125-26-255404) (XBRL) (1,329 words)
- [0001794546-26-000010 | 8-K | iXBRL Viewer | Carlsmed INC](/content/investors/node/7206/ixbrl-viewer/index.html): Carlsmed INC SEC filing: Form 8-K iXBRL on 05/05/2026 (0001794546-26-000010). (1,162 words)
- [investors/static-files/c330a74e-a6dd-4627-8b25-7f64334fe348/index.html](/content/investors/static-files/c330a74e-a6dd-4627-8b25-7f64334fe348/index.html) (792 words)
- [investors/static-files/390e5dda-bc10-4992-a162-5e7f3f8fcaa0/index.html](/content/investors/static-files/390e5dda-bc10-4992-a162-5e7f3f8fcaa0/index.html) (164 words)
- [0001794546-26-000005 | DEF 14A | iXBRL Viewer | Carlsmed INC](/content/investors/node/7156/ixbrl-viewer/index.html): Carlsmed INC SEC filing: Form DEF 14A iXBRL on 04/22/2026 (0001794546-26-000005). (22,401 words)
- [investors/static-files/bda0fd51-5333-4149-9618-a39cbc1193fa/index.html](/content/investors/static-files/bda0fd51-5333-4149-9618-a39cbc1193fa/index.html) (17 words)
- [investors/static-files/c5ccb180-4c57-4e49-b331-8547e1428ead/index.html](/content/investors/static-files/c5ccb180-4c57-4e49-b331-8547e1428ead/index.html) (94 words)
- [investors/static-files/c2b7aa88-a888-44f6-9195-5ed04be028c7/index.html](/content/investors/static-files/c2b7aa88-a888-44f6-9195-5ed04be028c7/index.html) (102 words)
- [investors/static-files/935549a1-aadb-4896-b215-139e2d142dd3/index.html](/content/investors/static-files/935549a1-aadb-4896-b215-139e2d142dd3/index.html) (41 words)
- [SEC Filing | Carlsmed](/content/investors/node/7246/html/index.html) (461 words)
- [investors/static-files/30732ff0-86d5-4c6b-ac72-b0463f23b722/index.html](/content/investors/static-files/30732ff0-86d5-4c6b-ac72-b0463f23b722/index.html) (43 words)
- [SEC Filing | Carlsmed](/content/investors/node/7241/html/index.html) (463 words)
- [SEC Filing | Carlsmed](/content/investors/node/7231/html/index.html) (555 words)
- [Form 4 for Oboyle Kevin C filed 06/22/2026](/content/investors/static-files/0852cebd-8b78-491c-9b1e-050493bacdf2/index.html) (242 words)
- [Document](/content/investors/static-files/5b0c9c03-1028-4955-a3d6-1c1e60ef6798/index.html) (282 words)
- [Document](/content/investors/static-files/e8485154-94cc-4e12-835d-73712ab497fd/index.html) (307 words)
- [Form 4 for Root Jonathan D filed 06/22/2026](/content/investors/static-files/145af9ad-d1fe-42db-8528-30959ab37312/index.html) (439 words)
- [Form 4 for Sidow Kevin filed 06/22/2026](/content/investors/static-files/86c6a926-0ce5-4348-a9a9-8adb90b1c2ff/index.html) (151 words)
- [0001193125-26-276633 | 4 | Carlsmed](/content/investors/sec-filings/sec-filing/4/0001193125-26-276633/index.html): Carlsmed Form 4 SEC Filing: Statement of changes in beneficial ownership of securities (41 words)
- [0001193125-26-276628 | 4 | Carlsmed](/content/investors/sec-filings/sec-filing/4/0001193125-26-276628/index.html): Carlsmed Form 4 SEC Filing: Statement of changes in beneficial ownership of securities (40 words)
- [Document](/content/investors/static-files/79777c06-b12f-4e86-9ff6-aaccf87c765c/index.html) (299 words)
- [Form 4 for Young Philip M filed 06/22/2026](/content/investors/static-files/500a9416-ecce-414f-9480-60635ffac48c/index.html) (291 words)
- [0001193125-26-276601 | 4 | Carlsmed](/content/investors/sec-filings/sec-filing/4/0001193125-26-276601/index.html): Carlsmed Form 4 SEC Filing: Statement of changes in beneficial ownership of securities (37 words)
- [0001193125-26-276599 | 4 | Carlsmed](/content/investors/sec-filings/sec-filing/4/0001193125-26-276599/index.html): Carlsmed Form 4 SEC Filing: Statement of changes in beneficial ownership of securities (37 words)
- [Document](/content/investors/static-files/80a2aaf8-d4e8-4ddf-a812-81a9033fdbfa/index.html) (280 words)
- [Document](/content/investors/static-files/ca9c975c-9cec-4bf3-b6b9-19303f7af895/index.html) (277 words)
- [Carlsmed Inc. to Report First Quarter 2026 Financial Results on May 5, 2026](/content/investors/node/7141/pdf/index.html) (158 words)
- [Management Team](/content/investors/static-files/a99d1da6-4e9c-4a93-810d-c0fec02ccfe3/index.html) (419 words)
- [Carlsmed, Inc. To Participate in the 25th Annual Needham Virtual Conference](/content/investors/node/7131/pdf/index.html) (116 words)
- [Document](/content/investors/static-files/c6dae4a8-739e-408d-87d2-d9b65285bb11/index.html) (2,578 words)
- [11th Annual International Spinal Deformity Symposium (ISDS) | Carlsmed](/content/investors/events/event-details/11th-annual-international-spinal-deformity-symposium-isds.html): 11th Annual International Spinal Deformity Symposium (ISDS) on Fri, 12/12/2025 - 00:00 (16 words)
- [Carlsmed Reports Third Quarter 2025 Financial Results and Raises Full-Year Guidance](/content/investors/node/6891/pdf/index.html) (685 words)
- [Carlsmed® Reports First Quarter 2026 Financial Results ](/content/investors/node/7201/pdf/index.html) (760 words)
- [Carlsmed aprevo� Lumbar 2-year Data Published in Global Spine Journal](/content/investors/node/6961/pdf/index.html) (475 words)
- [Carlsmed Announces first corra� personalized Cervical Plating Procedure](/content/investors/node/7051/pdf/index.html) (425 words)
- [Carlsmed Announces FDA Clearance for aprevo� Cervical Breakthrough Fusion Device](/content/investors/node/6361/pdf/index.html) (407 words)
- [Carlsmed Announces First aprevo� Bi-lateral Posterior Lumbar Interbody Fusion Procedure](/content/investors/node/7021/pdf/index.html) (541 words)
- [Compelling Clinical Data Released for Carlsmed�s aprevo� Technology](/content/investors/node/6416/pdf/index.html) (303 words)
- [Carlsmed Adds Industry Veteran, Kevin O�Boyle, to Board of Directors](/content/investors/node/6371/pdf/index.html) (320 words)
- [SEC Filing | Carlsmed](/content/investors/node/7206/html/index.html) (1,686 words)
- [FDA Grants Second Breakthrough Device Designation for Carlsmed Technology](/content/investors/node/6421/pdf/index.html) (299 words)
- [Carlsmed Announces Launch of Initial Public Offering](/content/investors/node/6571/pdf/index.html) (404 words)
- [Carlsmed�s aprevo� Powers First Personalized Cervical Spine Surgery](/content/investors/node/6666/pdf/index.html) (295 words)
- [Carlsmed Launches Cutting-Edge Digital Production Line, Revolutionizing Spine Surgery](/content/investors/node/6366/pdf/index.html) (305 words)
- [investors/static-files/43e281ed-94d0-435e-90b7-ec78a928def7/index.html](/content/investors/static-files/43e281ed-94d0-435e-90b7-ec78a928def7/index.html) (5,534 words)
- [Carlsmed Inc. to Report Third Quarter 2025 Financial Results on November 6, 2025](/content/investors/node/6846/pdf/index.html) (164 words)
- [Carlsmed Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026](/content/investors/node/7036/pdf/index.html) (171 words)
- [Document](/content/investors/static-files/d607fedd-b5a7-4d17-a980-bb44eb5dd8de/index.html) (733 words)
- [Form 8-K for Carlsmed INC filed 05/05/2026](/content/investors/static-files/16c01e37-0b5b-4f01-922b-dd65f82a89cd/index.html) (1,381 words)
- [Document](/content/investors/static-files/08d848c4-413e-4de3-9fa8-5baa8675be4b/index.html) (532 words)
- [Carlsmed Announces U.S. Launch of its aprevo� Technology Platform for Cervical Fusion Surgeries at the Cervical Spine Research Society (CSRS) 53rd Annual Meeting](/content/investors/node/6936/pdf/index.html) (444 words)
- [Carlsmed, Inc. Selected for Inclusion in Russell 2000� Index](/content/investors/node/6796/pdf/index.html) (529 words)
- [investors/static-files/77c4b799-285d-4ee1-b749-130e66699e3b/index.html](/content/investors/static-files/77c4b799-285d-4ee1-b749-130e66699e3b/index.html) (3,599 words)
- [Carlsmed�s aprevo� Personalized Interbody Implants Receive CMS New Technology Add-On Payment (NTAP) for Cervical Fusion Procedures](/content/investors/node/6676/pdf/index.html) (552 words)
- [0001193125-26-255404 | 8-K | iXBRL Viewer | Carlsmed INC](/content/investors/node/7221/ixbrl-viewer/index.html): Carlsmed INC SEC filing: Form 8-K iXBRL on 06/03/2026 (0001193125-26-255404). (495 words)
- [Carlsmed Announces Favorable Medicare Reimbursement Decision for Spinal Fusions with Custom-Made Anatomically Designed Devices](/content/investors/node/6376/pdf/index.html) (323 words)
- [investors/static-files/62569002-5a5a-4aac-a4d4-59932b437b9a/index.html](/content/investors/static-files/62569002-5a5a-4aac-a4d4-59932b437b9a/index.html) (3,107 words)
- [Carlsmed, Inc. To Participate in the 2026 Canaccord Genuity Musculoskeletal Conference ](/content/investors/node/7056/pdf/index.html) (120 words)
- [Carlsmed, Inc. To Participate in the Piper Sandler 37th Annual Healthcare Conference](/content/investors/node/6916/pdf/index.html) (140 words)
- [investors/static-files/ba51dca6-79f3-430c-a3de-a2508a311b02/index.html](/content/investors/static-files/ba51dca6-79f3-430c-a3de-a2508a311b02/index.html) (2,551 words)
- [SEC Filing | Carlsmed](/content/investors/node/7236/html/index.html) (601 words)
- [investors/static-files/6268f9b7-fcf4-431a-b603-cf37bedffbe7/index.html](/content/investors/static-files/6268f9b7-fcf4-431a-b603-cf37bedffbe7/index.html) (2,464 words)
- [0001794546-26-000011 | 10-Q | iXBRL Viewer | Carlsmed INC](/content/investors/node/7211/ixbrl-viewer/index.html): Carlsmed INC SEC filing: Form 10-Q iXBRL on 05/05/2026 (0001794546-26-000011). (20,433 words)
- [SEC Filing | Carlsmed](/content/investors/node/7161/html/index.html) (520 words)
- [Form 10-Q for Carlsmed INC filed 05/05/2026](/content/investors/static-files/ee77eb77-4756-473e-b265-8c19d93d6b60/index.html) (18,859 words)
- [Form DEFA14A for Carlsmed INC filed 04/22/2026](/content/investors/static-files/5bfd1dab-144b-4f7a-9577-1798876726b9/index.html) (419 words)
- [0001794546-26-000007 | ARS | Carlsmed](/content/investors/sec-filings/sec-filing/ars/0001794546-26-000007/index.html): Carlsmed Form ARS SEC Filing: An annual report to security holders (34 words)
- [0001794546-26-000011 | 10-Q | Carlsmed](/content/investors/sec-filings/sec-filing/10-q/0001794546-26-000011/index.html): Carlsmed Form 10-Q SEC Filing: Quarterly report which provides a continuing view of a company's financial position (58 words)
- [0001794546-26-000005 | DEF 14A | Carlsmed](/content/investors/sec-filings/sec-filing/def-14a/0001794546-26-000005/index.html): Carlsmed Form DEF 14A SEC Filing: Official notification to shareholders of matters to be brought to a vote ("Proxy") (52 words)
- [Form 8-K for Carlsmed INC filed 06/03/2026](/content/investors/static-files/c25576e1-f414-43ee-b253-ee903c8b1ff1/index.html) (504 words)
- [Document](/content/investors/static-files/8580dddc-f1af-4228-82ed-d79ab4aa1a28/index.html) (79 words)
- [0001794546-26-000006 | DEFA14A | Carlsmed](/content/investors/sec-filings/sec-filing/defa14a/0001794546-26-000006/index.html): Carlsmed Form DEFA14A SEC Filing: Additional proxy soliciting materials - definitive (33 words)
- [0001794546-26-000010 | 8-K | Carlsmed](/content/investors/sec-filings/sec-filing/8-k/0001794546-26-000010/index.html): Carlsmed Form 8-K SEC Filing: Report of unscheduled material events or corporate event (46 words)
- [SEC Filing | Carlsmed](/content/investors/node/7156/html/index.html) (21,116 words)
- [0001193125-26-255404 | 8-K | Carlsmed](/content/investors/sec-filings/sec-filing/8-k/0001193125-26-255404/index.html): Carlsmed Form 8-K SEC Filing: Report of unscheduled material events or corporate event (52 words)
- [Document](/content/investors/static-files/c902f80b-90f2-47d3-b689-442462e67eeb/index.html) (283 words)
- [Document](/content/investors/static-files/0a93ccde-78c1-4098-a5c3-2b4aecc1b91e/index.html) (128 words)
- [Form DEF 14A for Carlsmed INC filed 04/22/2026](/content/investors/static-files/dbcabb10-1723-42f3-a44a-577b986e089a/index.html) (20,516 words)
- [Document](/content/investors/static-files/fca80640-0760-4d2c-8ba9-c453da33f9d3/index.html) (1,053 words)
- [Carlsmed� Reports Second Quarter 2025 Financial Results](/content/investors/node/6741/pdf/index.html) (1,910 words)
- [J.P. Morgan Healthcare Conference | Carlsmed](/content/investors/events/event-details/jp-morgan-healthcare-conference/index.html): J.P. Morgan Healthcare Conference on Wed, 01/14/2026 - 16:30 (22 words)
- [Document](/content/investors/static-files/b9e65c81-9c95-4f87-b237-bbb6ded715f3/index.html) (227 words)
- [Document](/content/investors/static-files/623f7eae-a732-4de2-bf6d-a087dac87831/index.html) (319 words)
- [BofA Securities Health Care Conference | Carlsmed](/content/investors/events/event-details/bofa-securities-health-care-conference/index.html): BofA Securities Health Care Conference on Tue, 05/12/2026 - 16:20 (18 words)
- [Carlsmed Fourth Quarter 2025 Earnings Conference Call | Carlsmed](/content/investors/events/event-details/carlsmed-fourth-quarter-2025-earnings-conference-call.html): Carlsmed Fourth Quarter 2025 Earnings Conference Call on Wed, 02/25/2026 - 16:30 (16 words)
- [Canaccord Genuity Musculoskeletal Conference | Carlsmed](/content/investors/events/event-details/canaccord-genuity-musculoskeletal-conference/index.html): Canaccord Genuity Musculoskeletal Conference on Mon, 03/02/2026 - 00:00 (13 words)
- [Carlsmed Inc. to Report Second Quarter 2026 Financial Results on August 5, 2026](/content/investors/node/7251/pdf/index.html) (159 words)
- [Carlsmed, Inc. To Participate in Upcoming Investor Conferences](/content/investors/node/7171/pdf/index.html) (256 words)
- [investors/node/7261/ics/index.html](/content/investors/node/7261/ics/index.html) (28 words)
- [Carlsmed® Reports Fourth Quarter and Full Year 2025 Financial Results ](/content/investors/node/7071/pdf/index.html) (1,478 words)
- [Carlsmed® Reports Second Quarter 2025 Financial Results | Thu, 08/28/2025 - 18:09](/content/investors/news-releases/news-release-details/carlsmedr-reports-second-quarter-2025-financial-results-0.html): Q2’25 revenue of $12.1 million , 99% YOY growth Full year revenue guidance of $45.5M - $47.5M CARLSBAD, Calif. , Aug. 28, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, (1,703 words)
- [Carlsmed, Inc. Appoints Jennifer Kamocsay as Chief Legal Officer and Secretary](/content/investors/node/6801/pdf/index.html) (549 words)
- [Carlsmed Announces Filing of Registration Statement for Proposed Initial Public Offering](/content/investors/node/6491/pdf/index.html) (477 words)
- [Carlsmed Raises $52.5M in Series C Financing to Advance Personalized Spine Surgery](/content/investors/node/6411/pdf/index.html) (410 words)
- [Carlsmed Announces Pricing of Initial Public Offering](/content/investors/node/6576/pdf/index.html) (469 words)
- [Carlsmed Reports Third Quarter 2025 Financial Results and Raises Full-Year Guidance | Thu, 11/06/2025 - 16:02](/content/investors/news-releases/news-release-details/carlsmed-reports-third-quarter-2025-financial-results-and-raises.html): Third quarter revenue of $13.1 million, representing 98% growth YoY   Raising full year 2025 revenue guidance to $49 million - $50 million CARLSBAD, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering (802 words)
- [Carlsmed aprevo® Lumbar 2-year Data Published in Global Spine Journal | Tue, 01/06/2026 - 16:05](/content/investors/news-releases/news-release-details/carlsmed-aprevor-lumbar-2-year-data-published-global-spine.html): CARLSBAD, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the publication of a new retrospective cohort study in  Global Spine Journal demonstrating that 3D preoperative planning combined with patient-specific, anatomically (677 words)
- [Carlsmed Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025](/content/investors/node/6971/pdf/index.html) (555 words)
- [Carlsmed® Reports Fourth Quarter and Full Year 2025 Financial Results  | Wed, 02/25/2026 - 16:01](/content/investors/news-releases/news-release-details/carlsmedr-reports-fourth-quarter-and-full-year-2025-financial.html): Fourth quarter revenue of $15.2 million; 61% growth YoY  Full year revenue of $50.5 million; 86% growth YoY   CARLSBAD, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine (1,225 words)
- [Carlsmed Raises $52.5M in Series C Financing to Advance Personalized Spine Surgery | Mon, 03/18/2024 - 09:00](/content/investors/news-releases/news-release-details/carlsmed-raises-525m-series-c-financing-advance-personalized.html): CARLSBAD, Calif.--( BUSINESS WIRE )-- Carlsmed, an AI-enabled personalized surgery Medtech company, announced today a $52.5M Series C funding round co-led by B Capital and U.S. Venture Partners. These proceeds will be used to accelerate the commercialization of the aprevo ® personalized spine (426 words)
- [Carlsmed Announces FDA Clearance for aprevo® Cervical Breakthrough Fusion Device | Wed, 12/04/2024 - 08:00](/content/investors/news-releases/news-release-details/carlsmed-announces-fda-clearance-aprevor-cervical-breakthrough.html): CARLSBAD, Calif.--( BUSINESS WIRE )-- Carlsmed, Inc. (“Carlsmed” or the “Company”) a MedTech company pioneering AI-enabled personalized spine surgery, today announced FDA 510(k) clearance for the aprevo ® Cervical ACDF Interbody System. This milestone underscores Carlsmed’s commitment to advancing (432 words)
- [Carlsmed Inc. to Report Second Quarter 2025 Financial Results on August 28, 2025](/content/investors/node/6686/pdf/index.html) (165 words)
- [Carlsmed, Inc. Appoints Jennifer Kamocsay as Chief Legal Officer and Secretary | Mon, 09/29/2025 - 09:01](/content/investors/news-releases/news-release-details/carlsmed-inc-appoints-jennifer-kamocsay-chief-legal-officer-and.html): CARLSBAD, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced the appointment of Jenifer Kamocsay as Chief Legal Officer and Secretary, (558 words)
- [FDA Grants Second Breakthrough Device Designation for Carlsmed Technology | Wed, 09/20/2023 - 08:00](/content/investors/news-releases/news-release-details/fda-grants-second-breakthrough-device-designation-carlsmed.html): CARLSBAD, Calif.--( BUSINESS WIRE )-- Carlsmed announced today that the FDA granted Breakthrough Device designation for its aprevo® technology for treatment of patients with cervical spine disease. This is Carlsmed’s second Breakthrough Device designation, complementing the company’s family of (308 words)
- [Carlsmed Inc. to Report Third Quarter 2025 Financial Results on November 6, 2025 | Thu, 10/23/2025 - 16:01](/content/investors/news-releases/news-release-details/carlsmed-inc-report-third-quarter-2025-financial-results.html): CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its third quarter 2025 financial results after market close on Thursday, November 6, 2025. (183 words)
- [Compelling Clinical Data Released for Carlsmed’s aprevo® Technology | Mon, 01/08/2024 - 09:00](/content/investors/news-releases/news-release-details/compelling-clinical-data-released-carlsmeds-aprevor-technology.html): CARLSBAD, Calif.--( BUSINESS WIRE )-- Carlsmed announced today that new clinical data on its aprevo ® technology has been published in the Global Spine Journal. This landmark study of a patient-matched cohort concluded that the use of aprevo ® personalized interbody devices enables a significant (310 words)
- [Carlsmed Announces Pricing of Initial Public Offering | Tue, 07/22/2025 - 20:03](/content/investors/news-releases/news-release-details/carlsmed-announces-pricing-initial-public-offering/index.html): CARLSBAD, Calif. --(BUSINESS WIRE)--Jul. 22, 2025-- Carlsmed, Inc. (“Carlsmed”), a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced the pricing of its initial public offering of 6,700,000 shares of common stock at an initial (480 words)
- [Carlsmed, Inc. To Participate in the J.P. Morgan 2026 Healthcare Conference](/content/investors/node/6946/pdf/index.html) (112 words)
- [Carlsmed Announces Filing of Registration Statement for Proposed Initial Public Offering | Thu, 06/26/2025 - 11:38](/content/investors/news-releases/news-release-details/carlsmed-announces-filing-registration-statement-proposed.html): CARLSBAD, Calif.--( BUSINESS WIRE )-- Carlsmed, Inc. (“Carlsmed”), a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that it has publicly filed a registration statement on Form S-1 with the U.S. (480 words)
- [Carlsmed Adds Industry Veteran, Kevin O’Boyle, to Board of Directors | Tue, 10/08/2024 - 09:00](/content/investors/news-releases/news-release-details/carlsmed-adds-industry-veteran-kevin-oboyle-board-directors.html): CARLSBAD, Calif.--( BUSINESS WIRE )-- Carlsmed, the leader in personalized spine surgery, announced that Kevin O’Boyle has joined its Board of Directors and will serve as the Chair of the Audit Committee. Mr. O’Boyle previously served as a director of seven publicly traded companies, including (325 words)
- [Carlsmed Announces Launch of Initial Public Offering | Tue, 07/15/2025 - 00:00](/content/investors/news-releases/news-release-details/carlsmed-announces-launch-initial-public-offering-0.html): CARLSBAD, Calif.--(BUSINESS WIRE)--Carlsmed, Inc. (“Carlsmed”), a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced the launch of its initial public offering of 6,700,000 shares of common stock. (411 words)
- [Carlsmed Announces First aprevo® Bi-lateral Posterior Lumbar Interbody Fusion Procedure | Tue, 02/10/2026 - 09:00](/content/investors/news-releases/news-release-details/carlsmed-announces-first-aprevor-bi-lateral-posterior-lumbar.html): CARLSBAD, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the successful completion of the first posterior lumbar spine surgery using the Company’s aprevo ® Lumbar Bi-lateral Posterior System. (553 words)
- [Carlsmed’s aprevo® Powers First Personalized Cervical Spine Surgery | Mon, 07/28/2025 - 09:05](/content/investors/news-releases/news-release-details/carlsmeds-aprevor-powers-first-personalized-cervical-spine-0.html): CARLSBAD, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced the successful completion of the first aprevo ® cervical procedure on July 14, 2025 by Joseph (501 words)
- [Carlsmed Announces first corra™ personalized Cervical Plating Procedure | Wed, 02/18/2026 - 16:05](/content/investors/news-releases/news-release-details/carlsmed-announces-first-corratm-personalized-cervical-plating.html): The corra™ Cervical Plating System marks the debut of Carlsmed's patient-specific fixation portfolio CARLSBAD, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the first personalized cervical plating procedure using the corra™ (657 words)
- [Carlsmed Launches Cutting-Edge Digital Production Line, Revolutionizing Spine Surgery | Wed, 11/06/2024 - 09:00](/content/investors/news-releases/news-release-details/carlsmed-launches-cutting-edge-digital-production-line.html): CARLSBAD, Calif.--( BUSINESS WIRE )-- Carlsmed, a commercial-stage medical technology company and pioneer of the personalized spine surgery market, today announced the successful launch of its state-of-the-art digital production line. This innovative technology will enable the company to deliver (304 words)
- [Carlsmed Inc. to Report Second Quarter 2025 Financial Results on August 28, 2025 | Thu, 08/14/2025 - 09:05](/content/investors/news-releases/news-release-details/carlsmed-inc-report-second-quarter-2025-financial-results-august.html): CARLSBAD, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its second quarter 2025 financial results after market close on Thursday, August 28, 2025. (175 words)
- [Carlsmed Announces Preliminary Revenue for the Fourth Quarter and Full Year 2025 | Mon, 01/12/2026 - 08:05](/content/investors/news-releases/news-release-details/carlsmed-announces-preliminary-revenue-fourth-quarter-and-full.html): Fourth quarter 2025 revenue of ~$15.2 million, representing ~61% growth over Q4 2024 Full Year 2025 revenue of ~$50.5 million; representing ~86% growth over 2024 CARLSBAD, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology (566 words)
- [Carlsmed, Inc. To Participate in the J.P. Morgan 2026 Healthcare Conference | Tue, 12/16/2025 - 16:01](/content/investors/news-releases/news-release-details/carlsmed-inc-participate-jp-morgan-2026-healthcare-conference.html): CARLSBAD, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, Chairman and CEO of Carlsmed will be presenting at the J.P. Morgan 2026 Healthcare conference on Wednesday, January 14th at 4:30-5:10 pm PT in San (118 words)
- [Carlsmed Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026 | Wed, 02/11/2026 - 16:01](/content/investors/news-releases/news-release-details/carlsmed-inc-report-fourth-quarter-and-full-year-2025-financial.html): CARLSBAD, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its fourth quarter and full year 2025 financial results after market close on Wednesday, (180 words)
- [Management Team](/content/investors/static-files/3eefeff8-5286-4b45-8487-1c212c6a8698/index.html) (1,060 words)
- [Carlsmed® Reports First Quarter 2026 Financial Results  | Tue, 05/05/2026 - 16:01](/content/investors/news-releases/news-release-details/carlsmedr-reports-first-quarter-2026-financial-results.html): First quarter 2026 revenue of $16.1 million, representing 58% growth year-over-year Full year 2026 revenue guidance raised to $72 million to $77 million CARLSBAD, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company (1,754 words)
- [SEC Filing | Carlsmed](/content/investors/node/7221/html/index.html) (499 words)
- [SEC Filing | Carlsmed](/content/investors/node/7211/html/index.html) (19,148 words)
- [SEC Filings | Carlsmed](/content/investors/financial-information/sec-filings/index.html): View financial statements and other formal documents submitted to the U.S. Securities and Exchange Commission (SEC) for Carlsmed. (241 words)
- [Document](/content/investors/static-files/079b06f0-3652-40dc-a684-8c4d6f26e045/index.html) (314 words)
- [Board of Directors and Company Officers | Carlsmed](/content/investors/corporate-governance/board-of-directors/index.html): View the Board of Directors and Company Officers of Carlsmed who are a group of people who jointly supervise the activities of the organization. (1,247 words)
- [BTIG Snowbird: MedTech, Digital Health, Life Science & Diagnostic Tools Conference | Carlsmed](/content/investors/events/event-details/btig-snowbird-medtech-digital-health-life-science-diagnostic-tools-conference.html): BTIG Snowbird: MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tue, 02/10/2026 - 00:00 (22 words)
- [Carlsmed First Quarter 2026 Earnings Conference Call | Carlsmed](/content/investors/events/event-details/carlsmed-first-quarter-2026-earnings-conference-call.html): Carlsmed First Quarter 2026 Earnings Conference Call on Tue, 05/05/2026 - 16:30 (16 words)
- [Carlsmed Inc. to Report First Quarter 2026 Financial Results on May 5, 2026 | Tue, 04/14/2026 - 08:01](/content/investors/news-releases/news-release-details/carlsmed-inc-report-first-quarter-2026-financial-results-may-5.html): CARLSBAD, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its first quarter 2026 financial results after market close on Tuesday, May 5, 2026. (178 words)
- [25th Annual Needham Virtual Healthcare Conference | Carlsmed](/content/investors/events/event-details/25th-annual-needham-virtual-healthcare-conference/index.html): 25th Annual Needham Virtual Healthcare Conference on Mon, 04/13/2026 - 11:45 (19 words)
- [Stock Info | Carlsmed](/content/investors/stock-info/index.html): View the stock price and a historical stock chart for Carlsmed., chart showing pricing data with tools to compare and analyze data (392 words)
- [Carlsmed, Inc. To Participate in the 25th Annual Needham Virtual Conference | Wed, 04/01/2026 - 16:01](/content/investors/news-releases/news-release-details/carlsmed-inc-participate-25th-annual-needham-virtual-conference.html): CARLSBAD, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, CEO and Chairman, will be presenting at the 25th Annual Needham Virtual Conference on April 13, 2026 at 11:45 AM ET. (125 words)
- [Email Alerts - Unsubscribe | Carlsmed](/content/investors/unsubscribe/index.html): The Investor Relations website contains information about Carlsmed's business for stockholders, potential investors, and financial analysts. (23 words)
- [Events & Presentations | Carlsmed](/content/investors/events-presentations/index.html): The Investor Relations website contains information about Carlsmed's business for stockholders, potential investors, and financial analysts. (148 words)
- [Carlsmed Inc. to Report Second Quarter 2026 Financial Results on August 5, 2026 | Wed, 07/22/2026 - 16:01](/content/investors/news-releases/news-release-details/carlsmed-inc-report-second-quarter-2026-financial-results-august.html): CARLSBAD, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its second quarter 2026 financial results after market close on (164 words)
- [Carlsmed, Inc. To Participate in Upcoming Investor Conferences | Tue, 04/28/2026 - 16:01](/content/investors/news-releases/news-release-details/carlsmed-inc-participate-upcoming-investor-conferences.html): CARLSBAD, Calif., April 28, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, Chairman and Chief Executive Officer, will participate in the following investor conferences. Bank of America Global Healthcare Conference in Las (261 words)
- [Corporate Governance | Carlsmed](/content/investors/corporate-governance/documents-charters/index.html): Learn more about Carlsmed's corporate governance and view the company's governance documents and committee charters. (44 words)
- [Truist Securities MedTech Conference | Carlsmed](/content/investors/events/event-details/truist-securities-medtech-conference/index.html): Truist Securities MedTech Conference on Tue, 06/16/2026 - 10:00 (21 words)
- [Email Alerts | Carlsmed](/content/investors/resources/email-alerts/index.html): Be the first to know about the latest information from Carlsmed. Sign up for investor relations email alerts. (119 words)
- [Analyst Coverage | Carlsmed](/content/investors/stock-information/analyst-coverage/index.html): View a list of analysts following Carlsmed. (95 words)
- [Carlsmed Second Quarter 2026 Earnings Conference Call | Carlsmed](/content/investors/events/event-details/carlsmed-second-quarter-2026-earnings-conference-call.html): Carlsmed Second Quarter 2026 Earnings Conference Call on Wed, 08/05/2026 - 16:30 (21 words)
- [Contact IR | Carlsmed](/content/investors/resources/contact-ir/index.html): For investor related questions or requests for Carlsmed, please contact our Investor Relations department. (32 words)
- [Jefferies Global Healthcare Conference | Carlsmed](/content/investors/events/event-details/jefferies-global-healthcare-conference/index.html): Jefferies Global Healthcare Conference on Thu, 06/04/2026 - 00:00 (13 words)
- [wp-content/uploads/2025/10/mkt-123_r1_aprevocervicalcodingcard_161025_web-pdf.html](/content/wp-content/uploads/2025/10/mkt-123_r1_aprevocervicalcodingcard_161025_web-pdf.html) (540 words)
- [wp-content/uploads/2025/09/mkt-075_r5_aprevolumbarcodingcard-pdf.html](/content/wp-content/uploads/2025/09/mkt-075_r5_aprevolumbarcodingcard-pdf.html) (509 words)
- [MKT-108_R1_PAPP_1Pager_300326](/content/wp-content/uploads/2026/04/mkt-108_r1_patient-access-partnership-program-pdf.html) (204 words)
- [Carlsmed Announces U.S. Launch of its aprevo® Technology Platform for Cervical Fusion Surgeries at the Cervical Spine Research Society (CSRS) 53rd Annual Meeting | Wed, 12/03/2025 - 07:00](/content/investors/news-releases/news-release-details/carlsmed-announces-us-launch-its-aprevor-technology-platform.html): First 50+ cervical cases completed; observations on initial clinical experience to be presented by early adopters at the Carlsmed CSRS Lunch Workshop CARLSBAD, Calif., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the U.S. (641 words)
- [LBL-0003_LA Rev. 0.docx](/content/wp-content/uploads/2026/02/lbl-0003_la-aprevo-c2-ae-alif-llf-ifu-rev-0-pdf.html) (2,363 words)
- [Carlsmed, Inc. Selected for Inclusion in Russell 2000® Index | Mon, 09/22/2025 - 09:01](/content/investors/news-releases/news-release-details/carlsmed-inc-selected-inclusion-russell-2000r-index.html): CARLSBAD, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that effective after market close on September 22, 2025, it has been added to (536 words)
- [Carlsmed’s aprevo® Personalized Interbody Implants Receive CMS New Technology Add-On Payment (NTAP) for Cervical Fusion Procedures | Fri, 08/01/2025 - 09:05](/content/investors/news-releases/news-release-details/carlsmeds-aprevor-personalized-interbody-implants-receive-cms.html): CARLSBAD, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (“Carlsmed”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced that in the Hospital Inpatient Prospective Payment Systems Final Rule (IPPS) for fiscal year (FY) 2026, the (569 words)
- [Carlsmed, Inc. To Participate in the 2026 Canaccord Genuity Musculoskeletal Conference | Mon, 02/23/2026 - 16:01](/content/investors/news-releases/news-release-details/carlsmed-inc-participate-2026-canaccord-genuity-musculoskeletal.html): CARLSBAD, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, CEO and Chairman, will be presenting at the 2026 Canaccord Genuity Musculoskeletal Conference on March 2, 2026 at 11:30 AM CST in New Orleans, LA.   (123 words)
- [Carlsmed, Inc. To Participate in the Piper Sandler 37th Annual Healthcare Conference | Wed, 11/19/2025 - 16:01](/content/investors/news-releases/news-release-details/carlsmed-inc-participate-piper-sandler-37th-annual-healthcare.html): CARLSBAD, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, Chairman and CEO of Carlsmed, will be presenting at the 37th Annual Piper Sandler Healthcare conference on Wednesday, December 3rd at 9:00-9:25 am (141 words)
- [Carlsmed Announces Favorable Medicare Reimbursement Decision for Spinal Fusions with Custom-Made Anatomically Designed Devices | Mon, 08/05/2024 - 06:00](/content/investors/news-releases/news-release-details/carlsmed-announces-favorable-medicare-reimbursement-decision.html): CARLSBAD, Calif.--( BUSINESS WIRE )-- Carlsmed, the leader in personalized spine surgery, announced today that in the Hospital Inpatient Prospective Payment System Final Rule for fiscal year 2025, the Centers for Medicare & Medicaid Services (CMS) assigned spinal fusion cases with aprevo ® (324 words)
- [LBL-0015 _LA Rev. 0.docx](/content/wp-content/uploads/2026/02/lbl-0015-_la-aprevo-c2-ae-plif-tlif-ifu-rev-0-pdf.html) (1,745 words)
- [wp-content/uploads/2025/01/mkt-056-aprevo-hcp-brochure-pdf.html](/content/wp-content/uploads/2025/01/mkt-056-aprevo-hcp-brochure-pdf.html) (1,207 words)
- [Press Releases - Carlsmed](/content/newsroom/index.html): Newsroom (1,810 words)
- [wp-content/uploads/2026/01/lbl-0015-aprevo-c2-ae-posterior-and-transforaminal-lumbar-interbody-system-ifu-rev-10-pdf.html](/content/wp-content/uploads/2026/01/lbl-0015-aprevo-c2-ae-posterior-and-transforaminal-lumbar-interbody-system-ifu-rev-10-pdf.html) (1,731 words)
- [wp-content/uploads/2026/01/lbl-0037-aprevo-cervical-interbody-system-ifu-rev4-pdf.html](/content/wp-content/uploads/2026/01/lbl-0037-aprevo-cervical-interbody-system-ifu-rev4-pdf.html) (1,727 words)
- [wp-content/uploads/2026/01/lbl-0067-corra-cervical-plating-system-ifu-rev1-pdf.html](/content/wp-content/uploads/2026/01/lbl-0067-corra-cervical-plating-system-ifu-rev1-pdf.html) (1,275 words)
- [wp-content/uploads/2026/01/lbl-0003-aprevo-anterior-and-lateral-lumbar-interbody-system-ifu-rev-17-pdf.html](/content/wp-content/uploads/2026/01/lbl-0003-aprevo-anterior-and-lateral-lumbar-interbody-system-ifu-rev-17-pdf.html) (2,240 words)
- [Privacy Policy - Carlsmed](/content/privacy-policy/index.html): Privacy Policy
Last Updated: June 17, 2025

Carlsmed, Inc. (“Carlsmed,” “we,” or “us”) wants you to be familiar with how we collect, use and disclose information. This Privacy Policy describes our practices in connection with information that we collect through our websites, including at https://carlsmed.com/ and https://personalizedspine.com (the “Websites”). This Privacy Policy does not apply (2,578 words)
- [News | Carlsmed](/content/investors/news/index.html): View Carlsmed releases, including company news, investor relations information and more. (64 words)
- [Personnel and Applicant Privacy Policy - Carlsmed](/content/personnel-and-applicant-privacy-policy/index.html): California Personnel and Applicant Privacy PolicyLast Updated: June 17, 2025Carlsmed, Inc. (“Carlsmed,” “we,” or “us”) endeavor to protect the privacy of personal information. The purpose of this California Personnel and Applicant Privacy Policy (the “Policy”) is to notify California residents (“you”) of the processing of information that can reasonably be linked with you and that (2,017 words)
- [wp-content/uploads/2024/12/mkt-057-ver-0-patient-trifold-brochure-pdf.html](/content/wp-content/uploads/2024/12/mkt-057-ver-0-patient-trifold-brochure-pdf.html) (383 words)
- [myaprevo® - Carlsmed](/content/myaprevo/index.html): Gain insights about your personalized procedures by using myaprevo® to access patient plans and procedural data. Access real time information about your cases and track your progress and performance trends over time. (170 words)
- [Our Team - Carlsmed](/content/company/index.html): Our team is dedicated to improving outcomes and decreasing the cost of healthcare for spine surgery and beyond., Transforming Spine Surgery Through Personalized Solutions 
Our mission is to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. The Carlsmed aprevo® personalized surgery platform is designed to improve the standard of care for spine surgery one patient at a time. (561 words)
- [element_category/columns/index.html](/content/element_category/columns/index.html) (343 words)
- [Clinical Evidence - Carlsmed](/content/clinical-evidence/index.html): Clinical Evidence
Clinical evidence is essential, and we understand that meaningful clinical outcomes are paramount to delivering exceptional patient care. Across multiple published studies, the aprevo® platform has demonstrated improved surgical outcomes compared to the standard of care in both degenerative lumbar disease and adult spinal deformity.​ Any comparisons to (747 words)
- [Consumer Health Data Privacy Policy - Carlsmed](/content/consumer-health-data-privacy-policy/index.html): Consumer Health Data Privacy Statement
Last Updated: August 1, 2025

Pursuant to the Washington My Health My Data Act and the Nevada Consumer Health Privacy Law (collectively, the “Health Privacy Laws”), Carlsmed, Inc. (“we,” “us,” or “our”) is providing the following details regarding the categories of consumer health data that we collect, use, and share about Washington (821 words)
- [jan 2025 scroll - Carlsmed](/content/scrollsequence/jan-2025-scroll/index.html) (727 words)
- [fusion_tb_category/footer/index.html](/content/fusion_tb_category/footer/index.html) (238 words)
- [element_category/elements/index.html](/content/element_category/elements/index.html) (300 words)
- [element_category/sections/index.html](/content/element_category/sections/index.html) (206 words)
- [Personalized Procedural Solutions - Carlsmed](/content/personalized-procedural-solutions/index.html): Personalized Procedural Solutions 
Patient-specific Devices Designed to Optimize Surgical Workflows and Improve Clinical Outcomes
Utilizing patient data and advanced digital technologies, aprevo® empowers surgeons to personalize procedures to align with their unique preferences while addressing each patient's individual needs. The platform supports a broad (202 words)
- [Contact Us - Carlsmed](/content/contact-us/index.html): Corporate Headquarters 1800 Aston Ave.
Suite 100
Carlsbad, CA 92008 (760) 766 1923 

(888) 289 0604 

info@carlsmed.com   
Contact Us (303 words)
- [Coding & Reimbursement - Carlsmed](/content/coding-reimbursement/index.html): Coding & Reimbursement  

This information is not intended to instruct physicians or hospitals as to which codes to use for a particular diagnosis, service, supply, procedure, or treatment. Physicians and hospitals are solely responsible for identifying and submitting appropriate codes and charges for services rendered. They should contact (316 words)
- [Aprevo Test Sequence - Carlsmed](/content/scrollsequence/aprevo-test-sequence/index.html) (107 words)
- [Test for modals - Carlsmed](/content/test-for-modals/index.html): Leadership Team  
Mike Cordonnier
Chief Executive Officer 
Chief Executive Officer
Mike is the co-founder and serves as Chief Executive Officer and President of Carlsmed, he also serves as Chairman of the Board of Directors.

Mike has over two decades of experience successfully leading teams in introducing groundbreaking medical technologies. (55 words)
- [aprevo® Technology Platform - Carlsmed](/content/aprevo-technology-platform/index.html): Carlsmed® uses patient data and digital technologies to create optimal surgical plans and personalized aprevo® spine fusion devices., Technology Platform 
An end-to-end integrated platform designed for better surgical results, reduced revisions, and improved long-term outcomes.
Advancing what’s possible through personalized technology solutions.      

PRE-OP  
AI-enabled 3D Surgical Planning
The aprevo® planning software combines Al-enabled segmentation and prior outcomes data to develop personalized surgical plans (318 words)
- [Patents - Carlsmed](/content/patents/index.html): Patents    The following Carlsmed products, either alone or in combination with other products, are protected by one or more of the identified patents. The absence of a product name or patent number associated with any listed product does not constitute a waiver of Carlsmed’s intellectual property rights concerning that product.

This page is (149 words)
- [Home Page Scroll-Permanent Text - Carlsmed](/content/scrollsequence/home-page-scroll-permanent-text/index.html) (16 words)
- [Instructions For Use (IFU) - Carlsmed](/content/resources/index.html): Carlsmed®‘s mission is to improve outcomes and decrease the cost of healthcare for spine surgery and beyond., aprevo®  Resources 

Learn more about aprevo® by accessing the resources below. These resources include IFUs, brochures, and more.    

Brochures   

Patient Brochure     

HCP Brochure      

IFUs  English   aprevo® Anterior and Lateral Lumbar Interbody System (22 words)
- [Careers at Carlsmed](/content/carlsmed-careers/index.html): Join us in changing patient lives through personalized solutions. Explore career opportunities at Carlsmed., A Patient-Obsessed Culture and Team 

We are a rapidly growing company with a team of highly motivated individuals dedicated to tackling challenging projects. Join us in changing patient lives through personalized solutions. Explore career opportunities at Carlsmed.

Carlsmed is an equal opportunity employer. All applicants will be considered for employment (137 words)
- [Aprevo Test Sequence_updates - Carlsmed](/content/scrollsequence/aprevo-test-sequence_updates/index.html) (107 words)
- [With Callouts - Carlsmed](/content/scrollsequence/with-callouts/index.html) (27 words)
- [Investors - Carlsmed](/content/investors/index-2.html): Investor Relations     
Our Mission
We are committed to transforming healthcare by engaging and empowering patients. Carlsmed®'s proprietary algorithm helps guide preoperative decisions to align surgeon and patient expectations to increase patient satisfaction. aprevo® is all about you. Our patient-specific model has been designed to help you get (66 words)
- [Provider Locator - Carlsmed](/content/provider-locator/index.html): Carlsmed® has developed a breakthrough technology that is personalized to your spine and your unique needs., Provider Locator     
aprevo® Personalized Spine Provider 

The aprevo® Personalized Spine Provider program is designed to help prospective patients make informed decisions and connect them with surgeons who have experience with personalized aprevo® technology. (55 words)
- [Patient Stories - Carlsmed](/content/patient-stories/index.html): Patient Stories     
aprevo® Patient Stories 

Meet real patients who have experienced the aprevo® personalized spine journey. Their stories will show you how they have overcome debilitating spine pain and regained their lives with the help of their aprevo® Personalized Spine Provider. Meet Our Patients (58 words)

## Listings & Categories

- [author/wyatt/index.html](/content/author/wyatt/index.html) (334 words)
- [author/voxmd/index.html](/content/author/voxmd/index.html) (324 words)

## Resources

- [Full Page Index](/index.html): Browse all cached pages with rich metadata
- [About This Cache](/content/about.html): Methodology, technical details, and usage guidelines
- [XML Sitemap](/sitemap.xml): Machine-readable sitemap for crawler discovery
- [Robots.txt](/robots.txt): Crawler directives